Search

ObjectiveThis study aimed to compare the efficacy of albumin-bound paclitaxel combined with carboplatin (Nab-TC) with that of traditional solvent-based paclitaxel combined with carboplatin (TC) as neoadjuvant chemotherapy (NAC) regimens for primary epithelial ovarian cancer.MethodsEighty patients with advanced primary epithelial ovarian cancer admitted for treatment at the Harbin Medical University Cancer Hospital from January 2015 to January 2020 were retrospectively selected. All patients underwent surgery after 1–4 courses of NAC with Nab-TC or TC regimen. Among the patients included for study, 40 patients in each group.ResultsThe ORR in Nab-TC group was better compared to TC group (45% vs 40%), but the difference was not significant (P = 0.651). While the reduction rate of CA-125 value in the Nab-TC group was significantly better (P P = 0.012), and the patient’s quality of life was also better in the Nab-TC group (P ConclusionThe efficacy of the Nab-TC regimen as NAC for advanced primary epithelial ovarian cancer was non-inferior to that of the TC regimen along with a lower incidence of adverse reactions, a longer PFS and a higher quality of life, supporting its therapeutic value in the clinic.

Background: This study aimed to compare the efficacy of albumin-bound paclitaxel combined with carboplatin (Nab-TC) with that of traditional solvent-based paclitaxel combined with carboplatin (TC) as a neoadjuvant chemotherapy regimen for primary epithelial ovarian cancer. Methods: Seventy-six patients with advanced primary epithelial ovarian cancer admitted for treatment at the Third Affiliated Hospital of Harbin Medical University from January 2015 to August 2020 were retrospectively selected. All patients underwent surgery after two courses of neoadjuvant chemotherapy with a combination of paclitaxel and carboplatin. Among the patients included for study, 34 were in the Nab-TC program and 42 in the TC program. Results: After two courses of chemotherapy, the ORR value was 52.38% in the TC group and 58.82% in the Nab-TC group (P=0.355). The CA125 value of the Nab-TC group decreased by 88.28% and that of the TC group by 86.99% (P=0.358). Overall operation time, intraoperative blood loss and postoperative hospital time of patients in the Nab-TC group were lower (P>0.05) and length of total hospital stay was significantly lower (P0.05) and total incidence of nausea and vomiting as well as grade III and IV stages were significantly lower (PConclusion: The efficacy of the Nab-TC regimen as neoadjuvant chemotherapy for advanced primary epithelial ovarian cancer was equivalent to that of the TC regimen, along with a lower incidence of adverse reactions, supporting its therapeutic value in the clinic.

Background The current study aims to evaluate and compare the efficacy of post-operative chemotherapy using paclitaxel plus carboplatin or nedaplatin in patients with ovarian cancer, as well as the effects of different combinational therapies on the survival times of patients. Methods Ninety-four patients were recruited for the study. These ovarian cancer patients were admitted into the Cancer Hospital Affiliated with Harbin Medical University for surgery from January 2008 to October 2009. They were divided into different groups according to their post-operative chemotherapy schemes: paclitaxel plus carboplatin (CBP group, n = 48) and paclitaxel plus nedaplatin (NDP group, n = 46). Variance analysis was used to compare the effects of different chemotherapy schemes and pathological types of ovarian cancer on the level of CA125 in serum at different treatment time points. Univariate and multivariate analyses were employed to evaluate the survival times of patients in different groups and pathological types and ages. Results No significant differences were observed regarding the effects of various chemotherapy schemes (P = 0.561) and pathological types (P = 0.903) on the level of CA125 in serum of patients with ovarian cancer. However, the duration of chemotherapy had a profound impact on the level of CA125 in serum (P